In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cidara Therapeutics Inc.

www.cidara.com

Latest From Cidara Therapeutics Inc.

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Policy Regulation

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma

Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.

 

Infectious Diseases Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • K2 Therapeutics
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cidara Therapeutics Inc.
  • Senior Management
  • Jeffrey Stein, PhD, Pres. & CEO
    James Levine, CFO
    Taylor Sandison, MD, CMO
    Neil Abdollahian, CBO
    Les Tari, PhD, SVP, Rsch.
  • Contact Info
  • Cidara Therapeutics Inc.
    Phone: (858) 752-6170
    6310 Nancy Ridge Dr., Ste. 101
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register